Literature DB >> 12746231

Role of the bradykinin B2 receptor for the local and systemic inflammatory response that follows severe reperfusion injury.

Danielle G Souza1, Vanessa Pinho, Jorge L Pesquero, Eliane S Lomez, Steve Poole, Luiz Juliano, Ary Correa, M Salete de A Castro, Mauro M Teixeira.   

Abstract

1. Bradykinin (BK) appears to play an important role in the development and maintenance of inflammation. Here, we assessed the role of the BK B(2) receptor for the injuries that occur after ischemia and reperfusion (I/R) of the territory irrigated by the superior mesenteric artery. 2. Tissue (lung and duodenum) kallikrein activity increased after ischemia with greater enhancement after reperfusion. A selective inhibitor of tissue kallikrein, Phenylacetyl-Phe-Ser-Arg-N-(2,3-dinitrophenyl)-ethylenediamine (TKI, 0.001-10 mg ml(-1)), inhibited kallikrein activity in a concentration-dependent manner in vitro. In vivo, pretreatment with TKI (30 mg kg(-1)) prevented the extravasation of plasma and the recruitment of neutrophils. 3. Similarly, the bradykinin B(2) receptor antagonists, HOE 140 (0.01-1.0 mg kg(-1)) or FR173657 (10.0 mg kg(-1)), inhibited reperfusion-induced increases in vascular permeability and the recruitment of neutrophils in the intestine and lungs. 4. In a model of more severe I/R injury, HOE 140 (1.0 mg kg(-1)) inhibited the increase in vascular permeability, neutrophil recruitment, haemorrhage and tissue pathology. Furthermore, HOE 140 significantly inhibited the elevations of TNF-alpha in tissue and serum and partially prevented lethality. This was associated with an increase in the concentrations of IL-10 in tissue and serum. 5. Thus, our results demonstrate that, following intestinal I/R injury, there is an increase in tissue kallikrein activity and activation of BK B(2) receptors. B(2) receptor activation is essential for the development of inflammatory tissue injury and lethality. These results contrast with those of others showing that BK mostly exerts a protective role during I/R injury.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12746231      PMCID: PMC1573815          DOI: 10.1038/sj.bjp.0705200

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  48 in total

1.  Concentration-dependent effects of bradykinin on leukocyte recruitment and venular hemodynamics in rat mesentery.

Authors:  S Shigematsu; S Ishida; D C Gute; R J Korthuis
Journal:  Am J Physiol       Date:  1999-07

Review 2.  Kinin receptors.

Authors:  F Marceau; D R Bachvarov
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

3.  Suppressive effect of distinct bradykinin B2 receptor antagonist on allergen-evoked exudation and leukocyte infiltration in sensitized rats.

Authors:  C Bandeira-Melo; A S Calheiros; P M Silva; R S Cordeiro; M M Teixeira; M A Martins
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

4.  Effects of tachykinin NK1 or PAF receptor blockade on the lung injury induced by scorpion venom in rats.

Authors:  I M Matos; D G Souza; D G Seabra; L Freire-Maia; M M Teixeira
Journal:  Eur J Pharmacol       Date:  1999-07-09       Impact factor: 4.432

5.  Involvement of bradykinin B1 and B2 receptors in pulmonary leukocyte accumulation induced by Sephadex beads in guinea pigs.

Authors:  M S Perron; F Gobeil; S Pelletier; D Regoli; P Sirois
Journal:  Eur J Pharmacol       Date:  1999-07-02       Impact factor: 4.432

6.  Rat interleukin 6: expression in recombinant Escherichia coli, purification and development of a novel ELISA.

Authors:  G S Rees; C Ball; H L Ward; C K Gee; G Tarrant; Y Mistry; S Poole; A F Bristow
Journal:  Cytokine       Date:  1999-02       Impact factor: 3.861

7.  Autoregulation of bradykinin receptors: agonists in the presence of interleukin-1beta shift the repertoire of receptor subtypes from B2 to B1 in human lung fibroblasts.

Authors:  S B Phagoo; S Poole; L M Leeb-Lundberg
Journal:  Mol Pharmacol       Date:  1999-08       Impact factor: 4.436

8.  Bradykinin stimulates type II alveolar cells to release neutrophil and monocyte chemotactic activity and inflammatory cytokines.

Authors:  S Koyama; E Sato; H Nomura; K Kubo; M Miura; T Yamashita; S Nagai; T Izumi
Journal:  Am J Pathol       Date:  1998-12       Impact factor: 4.307

9.  Bradykinin and changes in microvascular permeability in the hamster cheek pouch: role of nitric oxide.

Authors:  M Félétou; E Bonnardel; E Canet
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739

10.  Bradykinin mediates myocardial ischaemic preconditioning against free radical injury in guinea-pig isolated heart.

Authors:  Z Q Jin; X Chen
Journal:  Clin Exp Pharmacol Physiol       Date:  1998-11       Impact factor: 2.557

View more
  15 in total

1.  NF-kappaB plays a major role during the systemic and local acute inflammatory response following intestinal reperfusion injury.

Authors:  Danielle G Souza; Angélica T Vieira; Vanessa Pinho; Lirlândia P Sousa; Anderson A Andrade; Cláudio A Bonjardim; Michael McMillan; Michael Kahn; Mauro M Teixeira
Journal:  Br J Pharmacol       Date:  2005-05       Impact factor: 8.739

Review 2.  Kallistatin suppresses cancer development by multi-factorial actions.

Authors:  Julie Chao; Pengfei Li; Lee Chao
Journal:  Crit Rev Oncol Hematol       Date:  2017-03-14       Impact factor: 6.312

3.  Comparative Effectiveness of Renin-Angiotensin System Antagonists in Maintenance Dialysis Patients.

Authors:  Theresa I Shireman; Jonathan D Mahnken; Milind A Phadnis; Edward F Ellerbeck; James B Wetmore
Journal:  Kidney Blood Press Res       Date:  2016-11-21       Impact factor: 2.687

4.  Mast cells drive mesenteric afferent signalling during acute intestinal ischaemia.

Authors:  Wen Jiang; Anthony J Kirkup; David Grundy
Journal:  J Physiol       Date:  2011-06-13       Impact factor: 5.182

5.  Comparative effects of angiotensin-converting enzyme inhibition and angiotensin-receptor blockade on inflammation during hemodialysis.

Authors:  Jorge L Gamboa; Mias Pretorius; Deanna R Todd-Tzanetos; James M Luther; Chang Yu; T Alp Ikizler; Nancy J Brown
Journal:  J Am Soc Nephrol       Date:  2011-12-08       Impact factor: 10.121

6.  Mechanisms of the anti-inflammatory effects of the natural secosteroids physalins in a model of intestinal ischaemia and reperfusion injury.

Authors:  Angélica T Vieira; Vanessa Pinho; Lucilia B Lepsch; Cristóforo Scavone; Ivone M Ribeiro; Therezinha Tomassini; Ricardo Ribeiro-dos-Santos; Milena B P Soares; Mauro M Teixeira; Danielle G Souza
Journal:  Br J Pharmacol       Date:  2005-09       Impact factor: 8.739

7.  Combination therapy for cerebral ischemia: do progesterone and noscapine provide better neuroprotection than either alone in the treatment?

Authors:  Manisha Kawadkar; Avinash S Mandloi; Nidhi Singh; Rajesh Mukharjee; Vipin V Dhote
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-01-06       Impact factor: 3.000

8.  Bradykinin does not induce gap formation between human endothelial cells.

Authors:  Pia Jungmann; Marianne Wilhelmi; Hans Oberleithner; Christoph Riethmüller
Journal:  Pflugers Arch       Date:  2007-10-02       Impact factor: 3.657

9.  Contribution of endogenous bradykinin to fibrinolysis, inflammation, and blood product transfusion following cardiac surgery: a randomized clinical trial.

Authors:  J M Balaguer; C Yu; J G Byrne; S K Ball; M R Petracek; N J Brown; M Pretorius
Journal:  Clin Pharmacol Ther       Date:  2012-12-24       Impact factor: 6.875

10.  Common pathways for activation of proinflammatory gene expression by G protein-coupled receptors in primary lung epithelial and endothelial cells.

Authors:  Weiyuan Chang; Jing Chen; Connie F Schlueter; Gary W Hoyle
Journal:  Exp Lung Res       Date:  2009-05       Impact factor: 2.459

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.